Fulgent Genetics (FLGT) Receives a Buy from Oppenheimer

By Jason Carr

Oppenheimer analyst Kevin DeGeeter maintained a Buy rating on Fulgent Genetics (FLGTResearch Report) today and set a price target of $75.00. The company’s shares closed last Friday at $32.53.

According to TipRanks.com, DeGeeter is a 5-star analyst with an average return of 21.8% and a 49.0% success rate. DeGeeter covers the Healthcare sector, focusing on stocks such as Interpace Diagnostics Group, Rocket Pharmaceuticals, and Ionis Pharmaceuticals.

Fulgent Genetics has an analyst consensus of Moderate Buy, with a price target consensus of $63.33.

See today’s analyst top recommended stocks >>

Fulgent Genetics’ market cap is currently $728.8M and has a P/E ratio of 284.90. The company has a Price to Book ratio of 8.80.

Based on the recent corporate insider activity of 18 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of FLGT in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Fulgent Genetics, Inc. is a technology company, which focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the overall quality of patient care. Its technology platform includes proprietary gene probes, advanced database algorithms, adaptive learning software, and proprietary laboratory information management systems. The company was founded on May 13, 2016 and is headquartered in Temple City, CA.